Home›Allergy & Immunology› Immune-Fibrotic Framework Links Endometriosis and Adenomyosis to Non-Hormonal Targets
Immune-Fibrotic Framework Links Endometriosis and Adenomyosis to Non-Hormonal TargetsNew non-hormonal treatment paths for endometriosis and adenomyosis
Frontiers in MedicinePublished September 21, 2026DOI ↗Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Consider this immune-fibrotic framework hypothesis-generating; no clinical data support changing practice.
This mini review synthesizes a conceptual framework rather than primary data. It reframes endometriosis and adenomyosis as related but not identical immune-fibrotic conditions involving macrophage-centered inflammatory, fibrotic, and neuroimmune programs. The authors argue that these shared and distinct mechanisms may explain overlapping clinical features while supporting separate therapeutic approaches.
The review proposes a phenotype-guided strategy for non-hormonal therapy, matching dominant immune-fibrotic programs to mechanism-based interventions. This is presented as a theoretical framework for future drug development, not as tested clinical guidance. No specific drug efficacy results, effect sizes, or trial outcomes are reported.
The authors identify non-hormonal immunopharmacological targets for patients with persistent symptoms or poor response to standard endocrine therapy. However, the review does not provide clinical trial data, and limitations, funding, and conflicts of interest are not reported. The proposed strategy therefore remains hypothesis-generating.
For clinicians, this review may help organize thinking about why some patients respond poorly to endocrine therapy and where non-hormonal mechanisms might eventually fit. It does not support changing current practice, and no safety or tolerability data are provided.
How this fits prior evidence
This mini review extends prior coverage of non-hormonal targets in endometriosis, including Hippo signaling and YAP1 activation, by proposing a broader immune-fibrotic framework centered on macrophage programs. It contrasts with prior coverage of hormonal therapies that significantly reduce pelvic pain, positioning non-hormonal approaches as relevant for patients with poor response to standard endocrine therapy. It also aligns with the note that Hippo pathway components require clinical validation, as this review likewise offers no clinical trial data. It does not address prior findings on PFMT plus hormonal therapy, ethanol sclerotherapy, or patient awareness of non-surgical diagnosis.
Living with endometriosis or adenomyosis can be a constant battle against pain and inflammation. While hormone treatments are the standard, they do not work for everyone. New research is looking at these conditions as immune and fibrotic issues, meaning they involve the body's immune cells and the way tissue scars over.
Instead of just focusing on hormones, this new approach looks at the specific ways the body reacts to these conditions. It focuses on macrophage-centered programs, which are the immune cells that drive inflammation and tissue changes. By understanding these specific pathways, doctors may be able to offer better options for patients who have persistent symptoms.
It is important to note that this research is a theoretical framework. It does not provide specific drug results or clinical trial data yet. It serves as a roadmap for future non-hormonal treatments that target the immune system rather than just the endocrine system.
What this means for you:
New research suggests using immune-focused treatments for patients who do not respond well to hormone therapy.
Common questions
What are the new non-hormonal options for endometriosis?
The research proposes a strategy that targets the immune and fibrotic programs of the disease. Instead of using hormones, this approach focuses on the specific ways immune cells and tissue scarring cause symptoms. This could offer a new path for people who do not find relief from standard endocrine treatments.
How is the treatment for adenomyosis changing?
Researchers are reframing adenomyosis as a condition involving immune-centered inflammation and neuroimmune programs. By identifying these specific biological pathways, doctors may eventually be able to use targeted medications to treat the underlying causes of the condition rather than just managing symptoms.
Are these new treatments available now?
No, these specific treatments are not available yet. The current research provides a theoretical framework and identifies potential targets for future drugs. It does not provide clinical trial data or specific drug results, but it helps map out future non-hormonal options.
Endometriosis and adenomyosis are commonly managed through endocrine suppression, analgesia and surgery, yet these approaches do not fully explain persistent pain, recurrence, fibrotic remodeling or variable treatment response. A growing body of immune and single-cell evidence supports a complementary view in which hormone-permissive tissue injury licenses macrophage-centered inflammatory, fibrotic and neuroimmune programs. This mini review reframes both disorders as related, but not identical, immune-fibrotic conditions and identifies tractable immunopharmacological nodes. We discuss macrophage plasticity, monocyte recruitment, cytokine and chemokine amplification, inflammasome signaling, TGF-β-driven fibrosis, oxidative and metabolic stress, neuroimmune pain signaling and targeted delivery. We argue that non-hormonal therapy should not be developed simply as an alternative to hormonal suppression. Instead, it should be tested as a phenotype-guided strategy that matches dominant immune-fibrotic programs to mechanism-based interventions while preserving reproductive safety. This framework highlights the need for biomarker-informed patient selection, compartment-specific endpoints and early attention to fertility-compatible translational design.
